For Zevra Therapeutics, last year’s approval of the rare lysosomal storage disorder drug Miplyffa appears to be the gift that ...
LaDuane Clifton, Zevra’s Chief Financial Officer said, “This non-dilutive capital strengthens our balance sheet by adding gross cash proceeds of $150 million, supporting continued investment in our ...
Zevra has sold its US Food and Drug Administration (FDA) priority review voucher (PRV) for $150m to an undisclosed party. The ...
Rare disease-focused biopharma Zevra Therapeutics has agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to an undisclosed buyer for $150 million.
Investing.com -- Shares of Zevra Therapeutics, Inc. ( Nasdaq: ZVRA) climbed 8% following the announcement that the company has entered into an agreement to sell its Rare Pediatric Disease Priority ...
Zevra Therapeutics, Inc. announced that it will receive a 2025 New Treatment Award for its product MIPLYFFA™ (arimoclomol) at the 21st Annual WORLDSymposium. Eight abstracts related to MIPLYFFA ...
About Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. is a commercial-stage company combining science, data, and patient needs to create transformational therapies for rare diseases with limited ...
Company will host conference call on Tuesday, Mar. 11, 2025, at 4:30 p.m. ETCELEBRATION, Fla., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a ...
About Zevra Therapeutics, Inc. Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient needs to create transformational therapies for diseases with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback